All times are listed in CET (Central European Time).
- Rocio Garcia-Carbonero (Madrid, Spain)
- Justo Castaño (Córdoba, Spain)
Lung and Digestive NETs: Convergent biology and site-specific molecular features
- Justo Castaño (Córdoba, Spain)
Pathological diagnosis: Tips and traps
- Aurel Perren (Bern, Switzerland)
Hormonal crisis prevention and management
- Antongiulio Faggiano (Rome, Italy)
Systemic therapy for advanced NENs: What’s new in the field?
- Rocio Garcia-Carbonero (Madrid, Spain)
27O - Lurbinectedin plus irinotecan in pre-treated gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs)
- Rocio Garcia-Carbonero (Madrid, Spain)
Abstract
Background
Lurbinectedin received FDA approval for the treatment of small cell lung cancer and has shown activity in neuroendocrine tumours from other primary sites (Eur J Cancer 2022; 172: 340-348). Previous data has shown synergy between lurbinectedin and irinotecan (Cancer Res2013;73 (8 Supl 1) Abs 5499). We show here the results from a phase I/II study expansion cohort evaluating lurbinectedin 2.0 mg/m2 plus irinotecan 75 mg/m2 with primary G-CSF prophylaxis in pre-treated G3 GEP-NECs.
Methods
Phase II expansion stage included a cohort of 20 pts with G3 (Ki67>20%) poorly differentiated NECs of GEP or unknown primary site after progression to platinum-based therapy. Primary endpoint was overall response rate (ORR) per RECIST v.1.1. Other endpoints were disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety and pharmacokinetics (PK).
Results
Primary tumour sites included oesophagus (2), stomach (4), pancreas (5), small bowel (2), colorectal (2), biliary tract (1) and unknown (4). Median Ki67 was 80% (60% of pts had Ki67 >55%). Thirteen pts (65%) were treated in second line, 5 pts (25%) in third line, and 2 pts (10%) in further lines. Confirmed partial response (PR) was reported in 3 pts (ORR=15%) and disease stabilization (SD) in 9 pts (DCR=60%). Median duration of the 3 PRs was 8.1 months. ORR was greater in NECs with lower Ki67 (28.6% in Ki67 20-55% vs. 8.3% in Ki67 >55%). Median PFS was 3.8 mo (95%CI, 1.4-9.0 mo) and 6-mo PFS rate was 30.1% (95%CI, 8.9-51.3%). Six of 20 pts (30%) showed PFS longer than that observed with prior therapy. Median OS was 6.9 mo (95%CI, 2.9-18.9 mo) and 6-mo and 1-year OS rates were 53.3% and 35.6%, respectively. Most common G3/4 toxicities were haematological: neutropenia (45%; G4 15%), anaemia (30%, all G3), and thrombocytopenia (15%; G4, 5%). There was one treatment-related death (bacteraemia). Total plasma clearance of lurbinectedin, irinotecan and SN38 were 9.5, 25.6 and 448.3 L/h, respectively, in line with reference values.
Conclusions
The combination of irinotecan and lurbinectedin is active in pts with pre-treated G3 GEP-NECs with manageable toxicity. The PK analysis showed no evidence of drug-drug interaction.
Clinical trial identification
EudraCT 2015-003602-16.
Legal entity responsible for the study
PharmaMar.
Funding
Has not received any funding.
Disclosure
R. Garcia-Carbonero: Financial Interests, Personal, Advisory Board: AAA, Advanz Pharma, Amgen, Astellas, Bayer, BMS, Boehringer Ingelheim, Esteve, Hutchmed, Ipsen, Midatech Pharma, MSD, Novartis, PharmaMar, Servier, Takeda; Financial Interests, Institutional, Research Grant: BMS, MSD, Pfizer; Non-Financial Interests, Personal, Leadership Role, Global PI of investigator-initiated clinical trials (AXINET, NICENEC, PEMBROLA): BMS, MSD, Pfizer; Other, Personal, Other, Honoraria received by spouse for advisory board or invited speaker roles: AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Genomica, Lilly, MSD, Merck, Novartis, Pfizer, PharmaMar, Roche, Sanofi, Servier, Takeda. G.M. Cote: Financial Interests, Personal, Advisory Role: Sonata Therapeutics; Financial Interests, Personal, Advisory Board: Daiichi Sankyo, Inc; Financial Interests, Personal, Funding: Servier Pharmaceuticals; PharmaMar; MacroGenics; Eisai; Merck KGaA/EMD Serono Research and Development Institute; SpringWorks; Repare Therapeutics; Foghorn Therapeutics; SMP Oncology; Jazz Pharmaceuticals; RAIN Oncology; BioAtla; Inhibrx; Ikena Oncology; C. B. Anton-Pascual: Financial Interests, Personal, Sponsor/Funding: Merck, Servier, Novartis, MSD, Leo Pharma and Fresenius Kabi.. T. Alonso Gordoa: Financial Interests, Personal, Sponsor/Funding: Ipsen, Adacap, Pfizer, Eisai, Lilly, Bayer, Janssen, Astellas, Novartis, MSD. A. Falcon Gonzalez: Financial Interests, Personal, Speaker’s Bureau: Novartis, Pfizer, Lilly, Seagen, Roche, Gilead, AstraZeneca, Daiichi Sankyo, Eisai, Grünenthal; Financial Interests, Personal, Advisory Role: AstraZeneca, Esteve. A. Gil Torralvo: Financial Interests, Personal, Speaker’s Bureau: Novartis, Pfizer, Daiichi Sankyo; Financial Interests, Personal, Advisory Role: AstraZeneca. S. Martinez, M. Siguero, M. Cullell, S. Fudio: Financial Interests, Personal, Member: PharmaMar. A. Zeaiter: Financial Interests, Personal, Member: PharmaMar; Financial Interests, Personal, Stocks/Shares: PharmaMar. All other authors have declared no conflicts of interest.
Invited Discussant abstract 27O
- Lucjan S. Wyrwicz (Warsaw, Poland)